EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study

Kazuya Hosokawa, Kohei Masaki, Masayuki Hirose, Takumi Inami, Yu Taniguchi, Shiro Adachi, Keimei Yoshida, Jun Yamashita, Nobuhiro Yaoita, Junichi Nakamura, Shun Minatsuki, Nobutaka Ikeda und 29 weitere

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.06.012 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Kazuya Hosokawa und 40 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Center for Clinical and Translational Res…. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Hypertension, Pulmonary, Pulmonary Embolism, Pyridines. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Government of Japan Ministry of Health Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Long-term real-world outcomes of edoxaban in chronic thromboembolic pulmonary hypertension (CTEPH) remain incompletely characterized despite emerging evidence, including the KABUKI randomized trial. OBJECTIVES: To evaluate long-term effectiveness and safety of edoxaban in patients with CTEPH using a nationwide registry. METHODS: We analyzed the CTEPH AC Registry, a multicenter prospective observational cohort. Patients with CTEPH receiving edoxaban at registration were included. The primary effectiveness endpoint was morbidity and mortality events, a composite of all-cause death, lung transplantation, rescue pulmonary endarterectomy or balloon pulmonary angioplasty, ≥15% decline in 6-minute walk distance with worsening World Health Organization functional class, or symptomatic venous thromboembolism. The primary safety endpoint was clinically relevant bleeding according to International Society on Thrombosis and Haemostasis criteria. RESULTS: Among 408 patients, median follow-up was 552 days. The cumulative incidence of morbidity and mortality events was 4.7%, 10.0%, and 14.1% at 1, 3, and 5 years, respectively. The cumulative incidence of clinically relevant bleeding was 3.2%, 4.8%, and 5.6%, respectively, and major bleeding occurred in 2.4% at 5 years. Symptomatic venous thromboembolism occurred in 1.5% at 5 years. Outcomes were broadly consistent across reperfusion history, World Health Organization functional class, edoxaban dose, and renal function strata. CONCLUSIONS: In this Japanese nationwide registry, long-term edoxaban therapy was associated with sustained clinical stability in patients with CTEPH. No clear late-emerging safety signal was observed, but extrapolation beyond Japan requires caution, particularly in patients with different body size, renal function, or concomitant medication profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsHypertension, PulmonaryPulmonary EmbolismPyridinesThiazolesAgedFemaleHumansMaleMiddle AgedChronic DiseaseHemorrhageJapanProspective StudiesRegistriesRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

anticoagulantschronic thromboembolic pulmonary hypertensionedoxabanpulmonary embolismpulmonary hypertensionregistriesvenous thromboembolism

Substanzen

edoxabanFactor Xa InhibitorsPyridinesThiazoles

Autor:innen und Institutionen

  • Faculty of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan. Electronic address:…
  • Faculty of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo, Japan.
  • Division of Cardiovascular Medicine, Kobe University Hospital, Kobe, Japan.
  • Department of Cardiology, Nagoya University Hospital, Nagoya, Japan.

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Government of Japan Ministry of Health Labour and Welfare
  • DAIICHI SANKYO COMPANY, LIMITED

Zitieren

APA

Hosokawa, K., Masaki, K., Hirose, M., Inami, T., Taniguchi, Y., Adachi, S., Yoshida, K., Yamashita, J., Yaoita, N., Nakamura, J., Minatsuki, S., Ikeda, N., Komura, N., Dohi, Y., Tanabe, N., Shigeta, A., Kubota, K., Ogihara, Y., Horimoto, K., …, & CTEPH AC registry Study Group (2026). Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.06.012

Vancouver

Hosokawa K, Masaki K, Hirose M, Inami T, Taniguchi Y, Adachi S, et al. Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.06.012

BibTeX
@article{Hosokawa2026,
  author = {Hosokawa, Kazuya and Masaki, Kohei and Hirose, Masayuki and Inami, Takumi and Taniguchi, Yu and Adachi, Shiro and Yoshida, Keimei and Yamashita, Jun and Yaoita, Nobuhiro and Nakamura, Junichi and Minatsuki, Shun and Ikeda, Nobutaka and Komura, Naohiro and Dohi, Yoshihiro and Tanabe, Nobuhiro and Shigeta, Ayako and Kubota, Kayoko and Ogihara, Yoshito and Horimoto, Koshin and Shimokawahara, Hiroto and Ueno, Yuki and Tamura, Yuichi and Anzai, Atsushi and Sato, Kimi and Ikemiyagi, Hidekazu and Sugiyama, Yoichi and Konishi, Hakuoh and Kimura, Kazuhiro and Shinke, Toshiro and Nakamura, Kazuto and Baba, Yuichi and Sugimura, Koichiro and Sugimoto, Koichi and Yamamoto, Eiichiro and Takama, Noriaki and Kikuchi, Noriko and Sada, Yoshiharu and Usui, Soichiro and Fukumoto, Yoshihiro and Abe, Kohtaro and CTEPH AC registry Study Group, CTEPH AC registry Study Group},
  title = {Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.06.012}
}
Kostenlos starten →